Tribute Pharmaceuticals Canada Inc. (fka TBUFF)

[BioSpecialist]

TBUFF is brutally Undervalued Gem


New Presentation
http://content.stockpr.com/tributepharma/media/0a26f60f9fe2b220d091c62d6123d81e.pdf

Summary

Canadian Business Includes 7 Marketed Products Including Recently Launched CAMBIA
Tribute sells products in both the primary care and specialty care markets.CAMBIA was launched in October 2012 to compete in the $150 million Canadian migraine market and is expected to be a key contributor to revenue growth in 2013.CAMBIA is a novel, patent-protected, fast-acting, new treatment option for people suffering from acute migraine attacks.Tribute has also entered into a promotional agreement with Pfizer Canada for the exclusive Canadian promotional rights to Gelfoam® in Canada. MycoVa is currently pending regulatory approval in Canada.

MEGA Product Pipeline :

Product Indication Geographic Right Market Size

Bezalip® SR Mixed dyslipidemia US & Canada $20 B

NeoVisc® Osteoarthritis of the knee Global $1.4 B

Soriatane® Moderate to severe psoriasis Canada $210 M

Uracyst® Interstitial cystitis Global $151 M

CAMBIA® Acute migraine headaches Canada $150 M

Collatamp G® Prevention of post-operative infection Canada $20 M

Gelfoam® Hemostatic device Canada $30 M

MycoVa™ Nail fungus Canada $30 M


Robert Harris - President &Chief Executive Officer

Founder of privately-held Tribute Pharmaceuticals which was acquired by the Company in 2011. Pharmaceutical industry veteran. Held executive positions at Biovail Corporation including VP of Business Development and GM of Biovail’s Canadian commercial group ,where he helped grow revenues to $150 M within four years, leading to Biovail’s acquisition by Valeant (NYSE:VRX) for $3.2 billion.20 years at Wyeth, now division of Pfizer (NYSE:PFE),where as Director of Sale s of Specialty Care group he built out Canadian market segment.Mr. Harris owns 20% of Tribute.

John Gregory- Director

Founded and built King Pharmaceuticals (formerly NYSE:KG) which was recently sold to Pfizer (NYSE:PFE) for $3.6 billion. Grew company from small family business to the world‘s 39th largest pharma company that was
included in S&P 500 Index with revenues over $1 billion.Now managing partner of SJ Strategic Investments , a family owned investment management firm. Mr. Gregory owns 12% of Tribute.

TBUFF´s Major Shareholders :

Elora Financial ... 6.8M
SJ Strategic ...6.4M
Harris (Robert) ....4.8M
Harris (Mary-Ann)... 4.1M
Goldman (Steven H) ....2.5M
Gregory (John M) ...1.7M
Thrasher ...1.3M
Tenney (Arnold)...1.2M
Kime (John J) ....125.0K
Clarke (Janice ...90.4K